Merck (MRK) Total Liabilities (2009 - 2026)
Merck's (MRK) quarterly Total Liabilities came in at $23.7 billion in Q2 2026, down 65.33% year-over-year from $68.5 billion in Q2 2025, and down 71.32% quarter-over-quarter from $82.8 billion in Q1 2026.
Analysis
Merck (MRK) Total Liabilities (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Total Liabilities for 18 consecutive years, with $23.7 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Liabilities fell 65.33% year-over-year to $23.7 billion in Q2 2026; TTM through Jun 2026 was $23.7 billion, a 65.33% decrease from a year earlier, with the FY2025 full-year figure at $21.3 billion, up 21161.0% from the prior year.
- Total Liabilities was $23.7 billion for Q2 2026 at Merck, down from $82.8 billion in the prior quarter.
- Over five years, Total Liabilities peaked at $82.8 billion in Q1 2026 and troughed at $100.0 million in Q4 2024.
- A 5-year average of $34.2 billion and a median of $22.5 billion in 2025 frame the typical range for Total Liabilities.
- Across the five-year window, Total Liabilities plunged 99.6% in 2023 and jumped 53277.6% in 2025, its largest moves.
- Over 5 years, Total Liabilities stood at $600.0 million in 2022, then tumbled by 58.33% to $250.0 million in 2023, then slumped by 60.0% to $100.0 million in 2024, then soared by 21161.0% to $21.3 billion in 2025, then climbed by 11.65% to $23.7 billion in 2026.
- The last three Total Liabilities figures came in at $23.7 billion (Q2 2026), $82.8 billion (Q1 2026), and $21.3 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 141.05 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 23.74 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 115.64 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 69.15 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 1.72 Bn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1.53 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 819.80 Mn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 1.67 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.74 Bn |
| Mar 31, 2026 | 82.75 Bn |
| Dec 31, 2025 | 21.26 Bn |
| Sep 30, 2025 | 15.90 Bn |
| Jun 30, 2025 | 68.46 Bn |
| Mar 31, 2025 | 66.72 Bn |
| Dec 31, 2024 | 100.00 Mn |
| Sep 30, 2024 | 72.97 Bn |
| Jun 30, 2024 | 68.98 Bn |
| Mar 31, 2024 | 125.00 Mn |
| Dec 31, 2023 | 250.00 Mn |
| Sep 30, 2023 | 250.00 Mn |
| Jun 30, 2023 | 65.73 Bn |
| Mar 31, 2023 | 125.00 Mn |
| Dec 31, 2022 | 600.00 Mn |
| Sep 30, 2022 | 62.56 Bn |
| Jun 30, 2022 | 63.78 Bn |
| Mar 31, 2022 | 600.00 Mn |
| Dec 31, 2021 | 400.00 Mn |
| Sep 30, 2021 | 57.63 Bn |